雷贝拉唑三联疗法治疗幽门螺旋杆菌相关性十二指肠溃疡疗效观察被引量：14

Study on the effects of raberazole triple therapy on helicobactor pylori related duodenal ulcer

下载PDF

导出

摘要目的:观察雷贝拉唑和奥美拉唑三联疗法治疗幽门螺旋杆菌(HP)相关性十二指肠溃疡2周疗程的溃疡愈合率、HP根除率、主要症状缓解率及其安全性。方法:经胃镜证实并且快速尿素酶试验阳性的十二指肠溃疡患者94例,采取随机分组,其中雷贝拉唑三联组(A组)48例,奥美拉唑三联组(B组)46例,2周为1疗程,停药4周后复查胃镜及快速尿素酶试验。结果:溃疡愈合率A组93.8%,B组74.0%,P<0.05;HP根除率A组91.6%,B组71.7%,P<0.05;1天疼痛缓解率A组58.3%,B组4.4%,P<0.01;3天疼痛缓解率A组68.7%,B组37.0%,P<0.01;不良反应发生率A组23.0%,B组26.3%,P>0.05。结论:雷贝拉唑三联2周疗法对十二指肠溃疡的疗效及症状缓解率明显优于奥美拉唑三联疗法,而不良反应发生率无显著性差异。 Objective：To observe the effects of raberazole and omeprazole triple therapy on helicobacter pylori （HP） related duodenal ulcer （DU） . Methods： 94 patients with DU comfirmed by gastroendoscopy and rapid urease test were divided into two groups, group A receiving raberazole triple therapy and group B receiving omeprazole triple therapy. The healing rate of ulcer, HP eradicate rate and the relieving rate were observed. Results ： The healing rate of ulcer, HP eradicate rate, one-day relieving rate of abdominal pain, three-day relieving rate of abdominal pain and the incidence rate of side effects were 93.8% ,91.6% ,58.3% ,68.7% and 23% in group A, compared with 74. 0%, 71.7%, 4. 4%, 37. 0% and 26. 3% in group B. Conclusion： The efficacy of raberazole triple therapy is much better than omeprazole triple therapy in treating DU. There are no significant difference in the side effects.

作者曹洋施瑞华

机构地区南京医科大学第一附属医院消化内科

出处《药学与临床研究》 2007年第6期473-476,共4页 Pharmaceutical and Clinical Research

关键词雷贝拉唑奥美拉唑幽门螺旋杆菌十二指肠溃疡 Raberazole Omeprazole Helicobacter pylori （HP） Duodenal ulcer （DU）

分类号 R975.6 [医药卫生—药品] R573.1 [医药卫生—消化系统]

引文网络
相关文献

参考文献15

1Kang JK, Kim E, Kim KH, et al. Association of Helicobacter pylori with gastritis and peptic ulcer diseases [J]. Yonsci Med J. 1991, 32(2) :157 -168.
2Borhan-Manesh F, Farnum JB. Study of Helicobacter pylori colonization of patches of heterotopic gastric mucosa (HGM) at the upper esophagus[J]. Dig Dis Sci, 1993, 38(1) :142 -146.
3Van der Hulst RW, Keller J J, Rauws EA, et al. Treatment of Helicobacter pylori infection: a review of the world literature[ J]. Helicobacter, 1996, 1 ( 1 ) :6 - 19.
4Tytgat GN. Shortcomings of the first - generation proton pump inhibitors [ J ] . Eur J Gastroenterol Hepatol, 2001,13(Suppl 1) :S29 -33.
5Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole [ J ]. Clin Pharmacokinet, 1996,31( 1 ) :9 -28.
6Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole , omeprazole and pantoprazole with other durgs [ J ]. Eur J Gastroenterol Hepatol, 1996;8(Suppl. l) ;S21 -5.
7Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor , and omeprazole in relation to S- mephenytoin 4'-hydroxylation status [ J ]. Clin Pharmacol Ther, 1995,58(2) : 143 - 154.
8郑青,吴叔明,柯美云,刘晓红,刘南植,但自力,苌新明,房殿春,肖天力,萧树东.雷贝拉唑与奥美拉唑三联疗法根除幽门螺杆菌多中心、随机、双盲、平行对照研究[J].胃肠病学,2002,7(5):272-276. 被引量：62
9王业建,顾本宇,关崎,郭长青.雷贝拉唑治疗消化性溃疡47例[J].医药导报,2003,22(7):456-457. 被引量：4
10Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents [ J ]. J Biol Chem, 1997, 272 ( 36 ) : 22438 - 22446.

二级参考文献39

1裴瑛,王宝恩,陈寿坡,吴铁镛.兰索拉唑治疗十二指肠溃疡的临床观察[J].中华内科杂志,1995,34(9):606-608. 被引量：23
2柯美云,蓝宇,王智风,邢进宏.功能性消化不良昼夜胃内pH变化[J].临床消化病杂志,1995,7(3):97-100. 被引量：13
3Dekk C P, Beker J A, Thjjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a Europe, an multicentre study [ J ].Aliment Pharmacol Ther , 1999, 13(2):179- 186.
4Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol, 1998 ; 93 (5) : 763 - 767.
5Bianco A, Cagossi M, Piraccini R, et al. The nightly spontaneous alkalinization of the stomach. Riv Eur Sei Med Farmaeol,1993 ; 15(1) : 17 -27.
6Robinson M. New-generation proton pump inhibitors; overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol,2001 ; 13(suppl. 1) :S43-S47.
7Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatoh 2001 ; 13 ( suppl. 1) : S29- S33.
8Fouad YM, Katz PO,Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther, 1999; 13 (10) : 1467-1471.
9Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther,2000; 14(9):1049-1056.
10Fackler WK,Ours TM,Vaezi MF,et al. Long-term effect of H2 RA therapy on nocturnal gastric acid breakthrough. Gastroenterology, 2002 ; 122 (3) : 625 -632.